These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22047592)

  • 1. α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease.
    Geerts H
    Expert Opin Investig Drugs; 2012 Jan; 21(1):59-65. PubMed ID: 22047592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia.
    AhnAllen CG
    Curr Opin Psychiatry; 2012 Mar; 25(2):103-8. PubMed ID: 22262029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology.
    Thomsen MS; Hansen HH; Timmerman DB; Mikkelsen JD
    Curr Pharm Des; 2010 Jan; 16(3):323-43. PubMed ID: 20109142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction.
    Cincotta SL; Yorek MS; Moschak TM; Lewis SR; Rodefer JS
    Curr Opin Investig Drugs; 2008 Jan; 9(1):47-56. PubMed ID: 18183531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.
    Cannon CE; Puri V; Vivian JA; Egbertson MS; Eddins D; Uslaner JM
    Neuropharmacology; 2013 Jan; 64():191-6. PubMed ID: 22659472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
    Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
    Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
    Martin LF; Freedman R
    Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease.
    Wallace TL; Porter RH
    Biochem Pharmacol; 2011 Oct; 82(8):891-903. PubMed ID: 21741954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease.
    Haydar SN; Dunlop J
    Curr Top Med Chem; 2010; 10(2):144-52. PubMed ID: 20166959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators.
    Ng HJ; Whittemore ER; Tran MB; Hogenkamp DJ; Broide RS; Johnstone TB; Zheng L; Stevens KE; Gee KW
    Proc Natl Acad Sci U S A; 2007 May; 104(19):8059-64. PubMed ID: 17470817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activators of α7 nAChR as Potential Therapeutics for Cognitive Impairment.
    Wang X; Bell IM; Uslaner JM
    Curr Top Behav Neurosci; 2020; 45():209-245. PubMed ID: 32451955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
    Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
    J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
    Beinat C; Banister SD; Herrera M; Law V; Kassiou M
    CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers.
    Tcheremissine OV; Castro MA; Gardner DR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):7-14. PubMed ID: 22059602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
    Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
    J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits.
    Leiser SC; Bowlby MR; Comery TA; Dunlop J
    Pharmacol Ther; 2009 Jun; 122(3):302-11. PubMed ID: 19351547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.
    Marquis KL; Comery TA; Jow F; Navarra RL; Grauer SM; Pulicicchio C; Kelley C; Brennan JA; Roncarati R; Scali C; Haydar S; Ghiron C; Terstappen GC; Dunlop J
    Psychopharmacology (Berl); 2011 Dec; 218(4):635-47. PubMed ID: 21643676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond acetylcholinesterase inhibitors for treating Alzheimer's disease: α7-nAChR agonists in human clinical trials.
    Russo P; Del Bufalo A; Frustaci A; Fini M; Cesario A
    Curr Pharm Des; 2014; 20(38):6014-21. PubMed ID: 24641224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia.
    Wallace TL; Bertrand D
    Expert Opin Ther Targets; 2013 Feb; 17(2):139-55. PubMed ID: 23231385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies.
    Lewis AS; van Schalkwyk GI; Bloch MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Apr; 75():45-53. PubMed ID: 28065843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.